Eloxx Pharmaceuticals Ltd. is developing compounds based on an ancient class of antibiotics that have the additional ability to treat genetic disorders caused by premature stop codons.

Roughly 12% of genetic diseases arise from nonsense mutations that insert a stop codon in mRNA coding regions and lead to truncated nonfunctional proteins.